Matthes Harald, Thronicke Anja, Hofheinz Ralf-Dieter, Baars Erik, Martin David, Huber Roman, Breitkreuz Thomas, Bar-Sela Gil, Galun Daniel, Schad Friedemann
Oncological Centre, Hospital Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany.
Institute of Social Medicine, Epidemiology and Health Economics and Medical Department of Gastroenterology, Infectiology and Rheumatology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Evid Based Complement Alternat Med. 2020 Feb 18;2020:7091039. doi: 10.1155/2020/7091039. eCollection 2020.
Up to 88% of oncological patients apply complementary therapies and up to 77% apply complementary mistletoe therapy in the context of integrative oncological approaches. An evidence-based consultation of oncological health professionals regarding complementary therapies used in Germany is missing. Therefore, a new S3-Guideline for Complementary Medicine in the Treatment of Oncological Patients is under development and is anticipated to be finalized in November 2020. It will be based on evidence-based publications and systematic reviews on complementary therapies in oncology. A recently published two-part systematic review on mistletoe treatment in oncology has been reevaluated.
The latest published systematic two-part review on mistletoe has been systematically proofread and checked in compliance with the Cochrane Handbook for Systematic Reviews of Intervention and the AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews) tool.
The here discussed two-part review is incomplete, lacks sound accuracy including insufficient assessment of the risk of bias, and contains imprecise statements. In addition, it does not sufficiently comply with the Cochrane Handbook for Systematic Reviews of Intervention and the AMSTAR 2 tool.
In view of the approaching release of a new guideline in the field of complementary therapies in oncology, the present statement draws attention to a lack of profound methodology of conductance of a recently released systematic review on mistletoe. In consequence, a comprehensive overview of published mistletoe studies, i.e., a meta-analysis with a sound methodology of conductance, is necessary.
在综合肿瘤治疗方法中，高达88%的肿瘤患者采用辅助疗法，高达77%的患者采用辅助槲寄生疗法。德国肿瘤健康专业人员缺乏关于辅助疗法的循证咨询。因此，一项关于肿瘤患者治疗中补充医学的新S3指南正在制定中，预计于2020年11月定稿。它将基于肿瘤学中辅助疗法的循证出版物和系统评价。最近发表的一篇关于肿瘤中槲寄生治疗的两部分系统评价已被重新评估。
对最新发表的关于槲寄生的两部分系统评价进行了系统校对，并根据《Cochrane干预系统评价手册》和AMSTAR 2（评估系统评价的测量工具）工具进行了检查。
这里讨论的两部分评价不完整，缺乏准确性，包括对偏倚风险的评估不足，并且包含不精确的陈述。此外，它没有充分符合《Cochrane干预系统评价手册》和AMSTAR 2工具。
鉴于肿瘤学辅助疗法领域新指南即将发布，本声明提请注意最近发表的关于槲寄生的系统评价缺乏深入的方法学。因此，有必要对已发表的槲寄生研究进行全面概述，即进行一项具有完善方法学的荟萃分析。
